Artelo Biosciences Announces Closing of $2.0 Million Public Offering

Rhea-AI Summary

Artelo Biosciences (Nasdaq: ARTL), a clinical-stage pharmaceutical company, has completed its previously announced public offering, raising $2.0 million in gross proceeds. The offering consisted of 441,210 shares of common stock priced at $4.40 per share and pre-funded warrants to purchase up to 13,335 shares at $4.399 per warrant.

The company has granted underwriters a 45-day option to purchase up to an additional 68,181 shares to cover over-allotments. R.F. Lafferty & Co. served as the sole book-running manager for the offering, which was conducted under Artelo's existing shelf registration statement.

Positive

• Raised $2.0 million in gross proceeds to support operations
• Additional potential capital through 45-day over-allotment option for 68,181 shares

Negative

• Potential dilution for existing shareholders
• Offering price of $4.40 per share may impact stock valuation

Insights

Financial Analyst

Artelo secured $2M in funding through a public offering to advance its clinical pipeline, but dilution impacts existing shareholders.

Artelo Biosciences has closed a $2.0 million public offering by issuing 441,210 common shares at $4.40 per share, along with pre-funded warrants for an additional 13,335 shares at effectively the same price. This capital raise is relatively modest for a clinical-stage pharmaceutical company focused on lipid-signaling pathways for cancer, pain, and neurological treatments.

The financing structure includes an over-allotment option allowing underwriters to purchase up to 68,181 additional shares within 45 days, potentially increasing the total raise. This offering was conducted through a shelf registration statement previously filed with the SEC, which streamlines the capital-raising process.

For a clinical-stage biotech, this funding likely provides some runway extension but appears insufficient for comprehensive late-stage clinical trials, which typically cost tens of millions. The modest size suggests this may be a bridge financing to either reach specific milestones or position the company for a larger future raise. The $4.40 share price and offering size indicate Artelo is operating with a relatively small market capitalization, typical of early clinical-stage companies.

While necessary for continued operations, this offering creates dilution for existing shareholders as new shares enter circulation. R.F. Lafferty & Co. served as the sole book-runner, indicating a relatively narrow distribution channel for the offering.

SOLANA BEACH, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced the closing of its previously announced underwritten public offering of 441,210 shares of its common stock at a price to the public of $4.40 per share and pre-funded warrants to purchase up to 13,335 shares of Artelo’s common stock at a price to the public of $4.399 per pre-funded warrant, which represents the per share public offering price of each share of Artelo’s common stock less the $0.001 per share exercise price for each pre-funded warrant.

The aggregate gross proceeds from the offering were approximately $2.0 million, prior to deducting underwriting discounts and other offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 68,181 shares of common stock at the public offering price per share, less the underwriting discounts to cover over-allotments, if any.

R.F. Lafferty & Co., Inc. acted as the sole book-running manager and underwriter for the offering.

The shares of common stock and pre-funded warrants were offered by the Company pursuant to a "shelf" registration statement on Form S-3 (File No. 333-273153), which was filed with the U.S. Securities and Exchange Commission (SEC) and declared effective by the SEC on July 14, 2023, and the accompanying prospectus contained therein.

The offering was made only by means of a prospectus supplement and accompanying prospectus. The final prospectus supplement and accompanying base prospectus relating to and describing the terms of the offering were filed with the SEC on October 1, 2025, and are available on the SEC’s website at www.sec.gov.

Copies of the prospectus supplement and the accompanying prospectus relating to this offering may be obtained, when available, on the SEC’s website at http://www.sec.gov or alternatively, from: R. F. Lafferty & Co., Inc., 40 Wall Street, Suite 3602, New York, NY 10005; (212) 293-9090.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Artelo Biosciences
Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways, with a diversified pipeline addressing significant unmet needs in anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Led by an experienced executive team collaborating with world-class researchers and technology partners, Artelo applies rigorous scientific, regulatory, commercial, and treasury management practices, including digital assets, to maximize stakeholder value. More information is available at www.artelobio.com and X: @ArteloBio.

Forward Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission, including our ability to raise additional capital in the future. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable securities laws.

Investor Relations Contact:
Crescendo Communications, LLC
Tel: 212-671-1020
Email: ARTL@crescendo-ir.com

FAQ

How much did Artelo Biosciences (ARTL) raise in its October 2025 public offering?

Artelo Biosciences raised $2.0 million in gross proceeds through an offering of common stock and pre-funded warrants.

What was the price per share for ARTL's October 2025 public offering?

The offering price was $4.40 per share for common stock and $4.399 per pre-funded warrant.

How many shares were offered in ARTL's October 2025 public offering?

Artelo offered 441,210 shares of common stock and pre-funded warrants to purchase up to 13,335 additional shares.

Who was the underwriter for Artelo Biosciences' October 2025 public offering?

R.F. Lafferty & Co., Inc. acted as the sole book-running manager and underwriter for the offering.

What is the over-allotment option in ARTL's October 2025 offering?

Underwriters received a 45-day option to purchase up to 68,181 additional shares at the public offering price, less underwriting discounts.